Tuesday, November 17, 2026
News

Phase 2,3 trial data of India's first mRNA COVID vaccine submitted to DCGI

SocialTwist Tell-a-Friend    Print this Page   COMMENT

By Shalini Bhardwaj

New Delhi | March 18, 2022 8:51:47 PM IST
Pune-based Gennova Biopharmaceuticals has submitted the phase-II and phase-III trials data of India's first mRNA COVID vaccine to the regulator Drugs Controller General of India (DCGI) on Friday, said sources.

The company has also developed an Omicron-specific vaccine which will be tested on humans for efficacy and immunogenicity.

Earlier the DG, Indian Council of Medical Research (ICMR) Dr Balram Bhargava informed that this vaccine is going to be useful in the future for the treatment of other diseases as well and India is heading towards becoming a vaccine superpower.

"India is heading towards becoming a vaccine superpower and the fact that these vaccines are going to be available for other diseases," said Dr Bhargava.

Dr V K Paul, Member (Health) Niti Aayog on the importance of mRNA vaccine had said, "This mRNA platform of vaccine is an asset today in wake of COVID and also beyond it for other diseases. It could be malaria, dengue or TB. There are so many diseases for which we are still hunting for affordable and effective vaccines."

Gennova Biopharmaceuticals has submitted phase-II and phase-III data of mRNA vaccine. The recommendations about vaccines will come only after evaluation by the Subject Expert Committee (SEC).

Meanwhile, India started vaccinating children aged 12 to 14 years as it expands its COVID-19 vaccination coverage on March 16.

The children in the said age group are administered Corbevax vaccine manufactured by Hyderabad-based Biological E. It is India's first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine against COVID-19.

Additionally, all above 60 years of age are now eligible for Precaution Dose, as the condition of comorbidity for this age group has been removed. The Precaution Dose (same as the previous two doses) is to be administered after 9 months (36 weeks) after the date of the second vaccination. (ANI)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Three killed, two injured as car plunges...
Delhi Court rejects Haryana judge's plea...
Badrinath temple doors closed for winter...
'If you want to know Sonia Gandhi, look ...
'Joyous season': Odisha officials offer ...
Patna: Nitin Nabin and wife offer 'arghy...
More...    
 
 Top Stories
US warns Americans of possible terr... 
India, Egypt aim to begin trade pac... 
Badrinath temple doors closed for w... 
"Ukraine needs clear parity to resp... 
"Making progress": US envoy Kushner... 
Delhi Court rejects Haryana judge's... 
MP CM Mohan Yadav inaugurates World... 
Three killed, two injured as car pl...